Northwire Canada EditionThursday, July 16, 2026
Sign inSubscribe
Northwire
⌕
HWY 0.370 +0.0% FCI 0.350 −7.9% GGAU 0.180 −5.3% KIRO 0.650 +1.6% LBNK 0.430 +0.0% BARU 0.040 +0.0% VCU 1.08 −5.3% NOBL 0.100 +0.0% SHL 0.355 +0.0% MTS 0.130 +0.0% FYL 0.090 +0.0% NUAG 5.42 −0.6% CAM 0.330 −1.5% SYH 0.398 −1.9% LOT 0.040 +0.0% CPL 0.210 +10.5% HWY 0.370 +0.0% FCI 0.350 −7.9% GGAU 0.180 −5.3% KIRO 0.650 +1.6% LBNK 0.430 +0.0% BARU 0.040 +0.0% VCU 1.08 −5.3% NOBL 0.100 +0.0% SHL 0.355 +0.0% MTS 0.130 +0.0% FYL 0.090 +0.0% NUAG 5.42 −0.6% CAM 0.330 −1.5% SYH 0.398 −1.9% LOT 0.040 +0.0% CPL 0.210 +10.5%
M&A / Property

BetterLife Pharma Announces Engagement with Shanghai-Based YAFO Capital

By The Northwire Desk — AI Analysis Dec 11, 2025 · 08:02 BETR · 0.055 BetterLife Pharma Inc.
BETR · Price

Executive Summary

  • BetterLife Pharma Inc. has entered into an engagement agreement with Shanghai‑based YAFO Capital to act as its exclusive advisor for securing strategic partnerships in Greater China (mainland China, Hong Kong, Taiwan, Macau).
  • The agreement also allows BetterLife to retain YAFO on a non‑exclusive basis for territories outside of Greater China.
  • The collaboration aims to accelerate development and potential commercialization of BETR‑001, a non‑hallucinogenic LSD derivative targeting neurological disorders, in the Asian market.

Key Details

  • Parties Involved: BetterLife Pharma Inc. (CSE: BETR) and YAFO Capital (Shanghai, China).
  • Scope of Advisory Services: Exclusive advisory for partnership development within Greater China; non‑exclusive advisory for other regions.
  • Objective: Identify and negotiate strategic partnerships to advance BETR‑001’s development, regulatory approval, and commercial rollout in Asian markets.
  • BETR‑001 Profile: Proprietary non‑hallucinogenic derivative of lysergic acid diethylamide (2‑bromo‑LSD); preclinical/IND‑enabling stage; potential indications include traumatic brain injury, PTSD, and cluster headache.
  • CEO Commentary (BetterLife): Emphasized excitement about leveraging YAFO’s expertise to bring non‑hallucinogenic neurological treatments to Asia.
  • Founder & CEO Commentary (YAFO): Highlighted BETR‑001’s differentiated therapeutic profile and the firm’s capability to accelerate strategic partnering in China.
  • Additional Pipeline: BetterLife also holds a drug candidate for viral infections and is exploring further strategic alternatives for its development.

Notable Quotes

“We are excited to work with the YAFO team to establish partnerships for the development of BETR‑001 and to bring potential non‑hallucinogenic treatments for neurological disorders to the Asian region.” – Dr. Ahmad Doroudian, CEO, BetterLife Pharma

“The non‑hallucinogenic profile of BETR‑001 represents a highly differentiated approach in neurological therapeutics, with significant clinical and commercial potential.” – Sean Jiang, Founder & CEO, YAFO Capital

Read the original news release →

More from BetterLife Pharma Inc.

Jun 25, 2026 · 08:01

Pre-revenue psychedelic-adjacent biotech secures CAD $2M financing and GMP manufacturing partner for BETR-001 IND filing.

M&A / Property Jun 22, 2026 · 08:01

BetterLife Pharma Secures CAD $2 Million in New Capital to Complete BETR-001 FDA IND Filing

Financings Jun 15, 2026 · 16:36

Pre-revenue psychedelic-adjacent biotech secures critical $2M lifeline amid severe liquidity crunch.

Financings Apr 10, 2026 · 16:29

BETR-001 IND Filing Delayed to 2H 2026 as Company Extends Debt Maturity

Financings Apr 08, 2026 · 17:22

“Tiny $500K private placement adds cash but deepens dilution for BETR‑001 pipeline”

Financings Apr 02, 2026 · 18:15

Betterlife issues 2.15M shares in debenture conversion

Financings